


## ORIGINAL RESEARCH

Proline-Rich Acidic Protein 1 (PRAP1) Protects the  
Gastrointestinal Epithelium From Irradiation-Induced Apoptosis

Alexandra A. Wolfarth,<sup>1</sup> Xu Liu,<sup>2</sup> Trevor M. Darby,<sup>3</sup> Darra J. Boyer,<sup>1</sup> Jocelyn B. Spizman,<sup>1</sup> Joshua A. Owens,<sup>3</sup> Bindu Chandrasekharan,<sup>1</sup> Crystal R. Naudin,<sup>3</sup> Krisztina Z. Hanley,<sup>1</sup> Brian S. Robinson,<sup>1</sup> Eric A. Ortlund,<sup>2</sup> Rheinallt M. Jones,<sup>3,4</sup> and Andrew S. Neish<sup>1,4</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, <sup>2</sup>Department of Biochemistry, <sup>3</sup>Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, <sup>4</sup>Emory Microbiome Research Center, Emory University School of Medicine, Atlanta, Georgia



## SUMMARY

Although highly expressed in the gastrointestinal tract, the function of proline-rich acidic protein 1 (PRAP1) is unknown. By using *Prap1* null mice, we show that PRAP1 protects the gastrointestinal epithelium from irradiation-induced apoptosis and significantly limits p21 expression.

**BACKGROUND & AIMS:** The intestinal epithelium must be resilient to physiochemical stress to uphold the physiological barrier separating the systemic compartment from the microbial and antigenic components of the gut lumen. Identifying proteins that mediate protection and enhancing their expression is therefore a clear approach to promote intestinal health. We previously reported that oral ingestion of the probiotic *Lactobacillus rhamnosus* GG not only induced the expression of several recognized cytoprotective factors in the murine colon, but also many genes with no previously described function, including the gene encoding proline-rich acidic protein 1 (PRAP1). PRAP1 is a highly expressed protein in the epithelium of the gastrointestinal tract and we sought to define its function in this tissue.

**METHODS:** Purified preparations of recombinant PRAP1 were analyzed biochemically and PRAP1 antisera were used to

visualize localization in tissues. *Prap1*<sup>-/-</sup> mice were characterized at baseline and challenged with total body irradiation, then enteroids were generated to recapitulate the irradiation challenge ex vivo.

**RESULTS:** PRAP1 is a 17-kilodalton intrinsically disordered protein with no recognizable sequence homology. PRAP1 expression levels were high in the epithelia of the small intestine. Although *Prap1*<sup>-/-</sup> mice presented only mild phenotypes at baseline, they were highly susceptible to intestinal injury upon challenge. After irradiation, the *Prap1*<sup>-/-</sup> mice showed accelerated death with a significant increase in apoptosis and p21 expression in the small intestinal epithelium.

**CONCLUSIONS:** PRAP1 is an intrinsically disordered protein highly expressed by the gastrointestinal epithelium and functions at exposed surfaces to protect the barrier from oxidative insult. (*Cell Mol Gastroenterol Hepatol* 2020;10:713-727; <https://doi.org/10.1016/j.jcmgh.2020.06.011>)

**Keywords:** Oxidative Stress; Intrinsically Disordered Proteins; p21; Small Intestine.

Induction of cellular-protective pathways and the associated effector molecules is particularly important in tissues that frequently are exposed to environmental

xenobiotics and oxidative stress, such as the gastrointestinal epithelium.<sup>1–3</sup> Such enterocytes are in intimate contact with the microbiota and their products as well as digestive components and ingested foodstuffs, requiring the epithelial cells perform their absorptive function while tolerating and responding to these exogenous stressors. When cells encounter exogenous insult that results in heightened oxidative stress and DNA damage, several pathways downstream of p53 activation determine cell fate and whether the cells will repair the DNA damage and continue in the cell cycle. In the case of overwhelming damage, they enact programmed cell death to safely eliminate injured cells.<sup>4,5</sup> Improper response to exogenous insult can lead to compromised barrier integrity, allowing luminal components to traverse the epithelial layer to subepithelial compartments where they induce heightened localized or systemic inflammation that can result in a variety of pathologic states.<sup>6–8</sup> Therefore, identifying proteins that promote a proper epithelial response to exogenous insult and enhancing their expression is a subject of intense investigative focus.

It increasingly is appreciated that the normal resident gut microbiota play a role in eliciting cytoprotection.<sup>9</sup> Corroborating this notion are studies showing that the intestines of germ-free mice that lack a microbiota are more susceptible to exogenous insult.<sup>2,10</sup> Furthermore, ingestion of putatively beneficial bacteria, also known as probiotics, including *Lactobacillus rhamnosus* GG, are known to elicit cytoprotection in the gut.<sup>11</sup> To identify potential novel cytoprotective genes induced by *Lactobacillus rhamnosus* GG in the murine intestine, transcriptomic analysis was performed on the colon 4 hours after oral gavage. Among the highest induced transcripts was a transcript coding for proline-rich acidic protein 1 (PRAP1).<sup>2</sup> PRAP1 is a 17-kilodalton secreted protein with no recognizable sequence homology.<sup>12</sup> Although *Prap1* originally was discovered to be highly expressed in the pregnant mouse uterus and later in the murine small intestine,<sup>13,14</sup> its function in the host remains largely unexplored. Studies using cultured transformed cell lines proposed that PRAP1 functions downstream of p53 signaling after DNA damage, with the disruption of PRAP1 function in this system rendering neoplastic cells more susceptible to chemotherapeutic agents.<sup>15</sup> Other studies described injection of pregnant mouse uteri with PRAP1 antisera and detected dysregulation in the expression of multiple proteins involved in apoptosis and inflammation, ultimately affecting embryo implantation.<sup>16</sup> Although PRAP1 has been implicated in cell survival, apoptosis, and response to injury, the in vivo function of PRAP1 in the gastrointestinal tract remains unknown.

We first aimed to characterize the structure and expression pattern of PRAP1 in vivo. We generated PRAP1 recombinant protein and PRAP1 antisera and found that PRAP1 is an intrinsically disordered protein highly expressed in the epithelia of the gastrointestinal tract in both mice and human beings. To determine the function of PRAP1 we challenged germ line *Prap1*<sup>-/-</sup> mice with irradiation to show that PRAP1 protected the enterocytes from


irradiation-induced apoptosis and that PRAP1 expression prolonged the survival of the mice after irradiation. Finally, manipulation of PRAP1 expression in both enteroids and an epithelial cell line showed that PRAP1 significantly decreased epithelial expression of p21 and improved cell viability after irradiation. Together, these data show that PRAP1 functions in vivo to protect the gastrointestinal epithelium from oxidative insult.

## Results

### *PRAP1 Is an Intrinsically Disordered Protein Conserved in Placental Mammals*

PRAP1 is a 17-kilodalton secreted protein composed of 149 amino acids. The first 20 amino acids on the N terminus serve as a signal peptide while the remaining amino acids form the secreted portion of the protein (Figure 1A). The amino acid sequence of the secreted protein does not have any detectable sequence homology with other proteins using the National Institutes of Health Basic Local Alignment Search Tool analysis,<sup>12</sup> and analysis of PRAP1 using Predictors of Natural Disordered Regions<sup>17</sup> predicts that PRAP1 has a high disordered score throughout the secreted portion of the protein and thus is predicted to be predominantly disordered (Figure 1B). Analysis of recombinant PRAP1 on size exclusion chromatography showed that PRAP1 eluted at a considerably larger functional size than its predicted molecular weight (16,570 daltons) (Figure 1C). This suggests that PRAP1 is either multimeric or has an extended conformation that is a fundamental characteristic of intrinsically disordered proteins. We next used circular dichroism (CD) to identify secondary structures within PRAP1, which showed a strong negative band near 200 nm, yet no significant signals around 208, 215, or 222 nm, indicating the absence of  $\alpha$  helix or  $\beta$  sheet in its secondary structure (Figure 1D).<sup>18</sup> Together, these data show that PRAP1 is intrinsically disordered, lacking any defined 3-dimensional structure. To identify species that express PRAP1 orthologs, the human PRAP1 amino acid sequence was queried in the Comparative Genomics feature of Ensembl (Cambridgeshire, UK).<sup>19</sup> Of the 126 species considered, PRAP1 orthologs were present in 51 species, all of which were placental mammals (Figure 1E). These data confirm that PRAP1 is indeed an intrinsically disordered protein, has no homology to other more functionally defined proteins, and evolved relatively late in evolution, at the emergence of placental mammals.


**Abbreviations used in this paper:** BSA, bovine serum albumin; CD, circular dichroism; FITC, fluorescein isothiocyanate; IDP, intrinsically disordered protein; IF, immunofluorescence; IL, interleukin; MTT, 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; pCMV, cytomegalovirus expression vector; PCR, polymerase chain reaction; PRAP1, proline-rich acidic protein 1; 6xHis, hexahistidine tag; TBI, total body irradiation; TBST, Tris-buffered saline with 0.1% Tween.

 Most current article

© 2020 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<https://doi.org/10.1016/j.jcmgh.2020.06.011>



**Figure 1. PRAP1 is an intrinsically disordered protein conserved in placental mammals.** (A) Amino acid sequence of human PRAP1 with signal peptide and secreted portion of the protein labeled. (B) Analysis of the PRAP1 amino acid sequence using the *Predictor of Natural Disordered Regions* (PONDR) software. The predicted ordered and disordered regions are plotted for each residue. (C) Size exclusion chromatogram of purified recombinant PRAP1 protein compared with a molecular weight standard: (a) thyroglobulin (670,000 daltons), (b)  $\gamma$ -globulin (158,000 daltons), (c) ovalbumin (44,000 daltons), (d) myoglobin (17,000 daltons), and (e) vitamin B12 (1350 daltons). (D) Circular dichroism spectra of recombinant PRAP1. (E) Analysis of the human PRAP1 amino acid sequence using the comparative genomics feature of Ensembl software. The number of PRAP1 orthologs identified in each taxonomic clade are indicated.

### PRAP1 Is Highly Expressed in the Epithelium of the Gastrointestinal Tract in Mice and Human Beings


To fully define the spatial and temporal expression of PRAP1, we generated antisera specific for mouse PRAP1. We first produced and purified recombinant mouse PRAP1 protein with a hexahistidine tag on the N terminus (6xHis-PRAP1) (Figure 2A). By using this recombinant 6xHis-PRAP1 protein, we generated antisera in rabbits. To validate specificity, we used this PRAP1 antisera to blot for PRAP1 in lysate from cells that overexpressed either human or mouse PRAP1. Although the commercially available PRAP1 polyclonal antibody (Proteintech, Rosemont, IL) produced a strong band at 20 kilodaltons for the cell lysate overexpressing human PRAP1, only our PRAP1 antisera was able to detect the overexpression of mouse PRAP1 (Figure 2B). We further validated our PRAP1 antisera by blotting whole tissue lysate collected from the small intestine and uterus of wild-type and *Prap1*<sup>-/-</sup> mice. The antisera detected a band at 17 kilodaltons in the wild-type tissue but not the *Prap1*<sup>-/-</sup> tissue (Figure 2C). Furthermore, immunofluorescence (IF) staining using our PRAP1 antisera in the small intestine of wild-type and *Prap1*<sup>-/-</sup> mice showed high specificity, with no detectable signal in the *Prap1*<sup>-/-</sup> tissue (Figure 2D). In summary, using recombinant mouse PRAP1 protein, we generated PRAP1 antisera suitable for the detection of PRAP1 in murine tissue.

Immunoblot analysis and measurement of transcript levels in the mouse showed that *Prap1* is highly abundant in the small intestine, with the relative abundance being

2-fold when compared with  $\beta$ -actin (Figure 3A and B). *Prap1* expression was highest in the proximal small intestine with expression diminishing along the caudal axis, becoming nearly undetectable in the distal large intestine. By using PRAP1 antisera, we detected abundant PRAP1 protein expressed exclusively in the gut epithelium (Figure 3C), with PRAP1 protein localization strongest in the perinuclear compartment of the cell (Figure 3D). To determine whether the PRAP1 expression pattern is similar in both mice and human beings, immunohistochemistry was performed on diagnostic biopsy specimens of the human ileum (Figure 3E). Immunohistochemical staining showed high PRAP1 expression in the enterocytes of the human small intestine, consistent with the expression pattern we detected in mice. A human colonic biopsy specimen served as a negative control and showed dramatically lower levels of PRAP1 staining in this tissue (Figure 3F). Together, these data show that PRAP1 is highly expressed in the epithelium of the small intestine in both mice and human beings.

### *Prap1*<sup>-/-</sup> Mice Have an Altered Gut Microbiota and Increased Inflammation

*Prap1* germline null mice were maintained in a specific pathogen-free barrier vivarium and monitored for any symptoms of spontaneous disease. *Prap1*<sup>-/-</sup> mice were aged successfully to 20 weeks and no spontaneous disease was apparent. At 10 weeks of age, the *Prap1*<sup>-/-</sup> mice showed no




**Figure 2.** Generation and validation of PRAP1 recombinant protein, PRAP1 antisera, and *Prap1*<sup>-/-</sup> mice. (A) Sodium dodecyl sulfate–polyacrylamide gel electrophoresis with Coomassie staining of recombinant 6xHis-PRAP1 expressed in *E coli* and purified by a Ni-NTA affinity chromatography column followed by a size exclusion column. (B) A human colonic epithelial cell line (SK-CO15) was transfected to overexpress human (H) and mouse (M) PRAP1. Cell lysates were blotted with a commercially available antibody specific for human PRAP1 (Proteintech, first blot) or with PRAP1 rabbit antisera generated using 6xHis-PRAP1 (second blot). (C) Western blot of small intestine and uterine whole tissue from wild-type and *Prap1*<sup>-/-</sup> mice, blotted with PRAP1 antisera introduced in panel B. (D) Immunofluorescence staining of wild-type and *Prap1*<sup>-/-</sup> duodenum using PRAP1 antisera. Whole-body knockout mice were procured from MMRRC-UC Davis and backcrossed to obtain a fully congenic C57BL/6 background. Scale bar: 100  $\mu$ m. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KO, knockout, SI, small intestine; WT, wild-type; UT, uterine tissue.

difference in body weight, gut barrier architecture, or in the expression levels of proliferative or pro-apoptotic proteins in the small intestine (Figure 4A–E). To investigate whether the *Prap1*<sup>-/-</sup> mice have an altered gut microbiota, we sequenced the 16S ribosomal RNA gene from microbial DNA isolated from the small intestinal lumen of *Prap1*<sup>-/-</sup> and wild-type littermate controls. We detected a change in the ratio of Bacteroidetes:Firmicutes in which wild-type mice had an average ratio of 82:15 and *Prap1*<sup>-/-</sup> mice had a statistically significant shift in this ratio, with an average ratio of 66:29 (Figure 4F and G). Because *Prap1*<sup>-/-</sup> mice had a significant shift in the abundances of dominant bacterial phyla, we next sought to determine whether the *Prap1*<sup>-/-</sup> mice had any significant inflammatory differences. To detect systemic inflammation at baseline, we measured the levels of proinflammatory cytokines in the sera using a multiplex enzyme-linked immunosorbent assay that simultaneously detects the level of 10 proinflammatory cytokines. Sera collected from *Prap1*<sup>-/-</sup> mice had increased levels of proinflammatory cytokines (Figure 5A), with significantly higher interleukin (IL)2, IL4, and IL12p70 (Figure 5B). Along with increased systemic cytokines, the *Prap1*<sup>-/-</sup> mice also had an increased IL12 $\beta$  transcript in colonic tissue (Figure 5C). To determine the extent of local inflammation in the gut we measured the amount of secreted IgA and found there was no difference in the amount of secreted fecal IgA between wild-type and *Prap1*<sup>-/-</sup> littermates (Figure 5D). To determine whether the altered microbiota and increased cytokine expression could be attributed to a defective gut barrier, we orally gavaged adult wild-type and *Prap1*<sup>-/-</sup> littermates with fluorescein isothiocyanate (FITC) dextran and collected the sera 4 hours later. There was no difference in serum FITC dextran, indicating no significant alteration in gut permeability (Figure 5E). In summary, these data show that although *Prap1*<sup>-/-</sup> mice have an altered microbiota and increased cytokine expression, they do not show any serious mucosal defects when unchallenged.

### *Prap1*<sup>-/-</sup> Mice Are More Susceptible to Radiologic Challenge

Total body irradiation (TBI) introduces a significant amount of cellular oxidative stress that results in DNA damage and rapid apoptosis of dividing stem cells in the gastrointestinal epithelium. To investigate whether *Prap1*<sup>-/-</sup> mice were more susceptible to this exogenous insult, we challenged mice with a lethal dose of TBI. *Prap1*<sup>-/-</sup> females and males lost significantly more body weight when compared with wild-type littermate controls starting at 3 days after irradiation (Figure 6A). Furthermore, *Prap1*<sup>-/-</sup> mice had significantly reduced viability after irradiation, with a median survival of 5 days, whereas the wild-type controls had a median survival of 8 days (Figure 6B). To compare early cellular injury in the small intestine of wild-type and *Prap1*<sup>-/-</sup> mice, apoptotic cells were labeled with terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining 6 hours after irradiation (Figure 6C). At the tissue level, *Prap1*<sup>-/-</sup> mice had significantly more apoptotic cells per crypt compared with wild-type mice (Figure 6E). To compare injury at a later time point, wild-type and *Prap1*<sup>-/-</sup> mice were killed 72 hours after irradiation and the amount of apoptosis in the small intestine was measured via cleaved caspase-3 immunofluorescence. Again, the *Prap1*<sup>-/-</sup> mice had significantly higher levels of apoptosis in the epithelium of the small intestine compared with wild-type controls (Figure 6D and F). By 96 hours after irradiation when *Prap1*<sup>-/-</sup> mice were approaching 75% initial body weight, their small intestine had a significantly higher amount of *Bax* expression, indicating a significant increase in apoptosis compared with wild-type controls (Figure 6G). Although the *Prap1*<sup>-/-</sup> mice had increased apoptosis, they did not have any significant changes in *Pcna* expression, indicating no significant change in proliferation compared with wild-type controls (Figure 6H). To determine whether the increased apoptosis in the *Prap1*<sup>-/-</sup> mice coincided with increased gut




**Figure 3. PRAP1 is highly expressed by the epithelium of the gastrointestinal tract in mice and human beings.** (A) Quantification of *Prap1* transcript measured via quantitative PCR in the indicated tissues from 8-week-old wild-type C57BL/6 mice ( $n = 3$  mice). (B) Western blot analysis for the detection of PRAP1 protein abundance in the indicated tissues dissected from 8-week-old wild-type C57BL/6 mice. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. Images are representative of 3 mice per tissue collected. (C) Immunofluorescence for the detection of PRAP1 (green) in the duodenum of 8-week-old wild-type C57BL/6 mice or *Prap1*<sup>-/-</sup> mice. Images are representative of the analysis of 5 mice per tissue collected. (D) Immunofluorescence staining of PRAP1 (green) in the duodenum of 8-week-old wild-type mice at 60 $\times$  magnification. (E and F) Immunohistochemistry staining for the detection of PRAP1 (brown) in the human ileum (E) and colon (F). Image is representative of 3 subjects. Prox, proximal.

barrier permeability, we orally gavaged wild-type and *Prap1*<sup>-/-</sup> mice with FITC dextran 72 hours after TBI. Quantification of serum FITC dextran levels showed no difference between wild-type and *Prap1*<sup>-/-</sup> mice, suggesting no significant change in gut barrier permeability at this particular time point (Figure 6J). Lastly, wild-type mice significantly increased *Prap1* expression in the small intestine 96 hours after irradiation compared with unchallenged wild-type mice or mice 6 hours after irradiation (Figure 6J). Taken together, these data show that PRAP1 expression protects the epithelium from irradiation-induced apoptosis 6 hours after challenge and this protection persists for days later,

coinciding with increased expression of PRAP1 by the gut epithelium.

### *PRAP1 Protects Enteroids From Irradiation-Induced Apoptosis by Limiting p21 Expression*


To determine whether PRAP1 protection from irradiation could be observed in an isolated epithelial model, we harvested crypts from the small intestine of wild-type and *Prap1*<sup>-/-</sup> mice to culture enteroids ex vivo. On day 5 of culture, the enteroids were irradiated with 2 Gy and viability of the enterocytes was measured via the metabolic reduction



**Figure 4.** *Prap1*<sup>-/-</sup> mice have an altered microbiota in the small intestine. (A) The body weight of wild-type and *Prap1*<sup>-/-</sup> littermates at 10 weeks old. (B) H&E staining of wild-type and *Prap1*<sup>-/-</sup> small intestine. Images are representative of 3 mice per group. (C) Quantification of villi and crypt length in the small intestine of wild-type and *Prap1*<sup>-/-</sup> mice. Significance was determined using an unpaired *t* test ( $n = 3$  mice).  $*P < .05$ . (D and E) Quantitative PCR analysis of *Pcna* (D) and *Bax* (E) expression in whole tissue from the small intestine of wild-type and *Prap1*<sup>-/-</sup> mice. Expression levels are relative to *Gapdh*. Significance was determined using an unpaired *t* test.  $*P < .05$  ( $n = 6$  mice). (F) Pie chart comparison of the average Bacteroidetes:Firmicutes phyla ratio in the small intestine of wild-type and *Prap1*<sup>-/-</sup> littermates measured via 16S ribosomal RNA sequencing ( $n \geq 12$  mice). (G) Relative abundance of Firmicutes and Bacteroidetes in the small intestine of wild-type and *Prap1*<sup>-/-</sup> littermates. Significance was determined using an unpaired *t* test ( $n \geq 12$  mice).  $*P < .05$ . All data are graphed as the means  $\pm$  SEM. Bax RA, Bax relative abundance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KO, knockout; *Pcna* RA, *Pcna* relative abundance; WT, wild-type.

of 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) to formazan. At 48 hours after irradiation, the *Prap1*<sup>-/-</sup> enteroids had a significant decrease in the percentage of viability compared with wild-type controls (Figure 7A). To determine whether this decrease in viability could be attributed to an increase in apoptosis, we stained the enteroids for cleaved caspase-3 at 24 hours after

irradiation (Figure 7B). Enumeration of cleaved caspase-3-positive enteroids showed *Prap1*<sup>-/-</sup> enteroids had a significantly higher percentage undergoing apoptosis after irradiation (Figure 7C). In summary, these data show that PRAP1 is capable of protecting the epithelium from irradiation-induced apoptosis in an isolated epithelial system.




**Figure 5.** *Prap1*<sup>-/-</sup> mice have increased inflammation but no significant intestinal barrier defect. (A) A multiplex enzyme-linked immunosorbent assay (ELISA) was used for the detection of 10 proinflammatory cytokines in sera of 10-week-old wild-type and *Prap1*<sup>-/-</sup> littermates. Data are shown as a heat map, with red indicating a higher than average concentration. Each column represents 1 mouse. (B) Graphic representation of significantly different cytokine levels shown in panel A, including IL2, IL4, and IL12p70. Statistical significance was determined using an unpaired *t* test (*n* = 5 mice). \**P* < .05. (C) Quantification of IL12 $\beta$  transcript levels measured via quantitative PCR in the colon of 10-week-old wild-type and *Prap1*<sup>-/-</sup> mice relative to the abundance of  $\beta$ -actin. Statistical significance was determined using an unpaired *t* test (*n* = 5 mice). \**P* < .05. (D) Quantification of IgA levels in fecal pellets collected from 10-week-old wild-type and *Prap1*<sup>-/-</sup> mice, measured via ELISA. Statistical significance was determined using an unpaired *t* test (*n* = 5 mice). (E) Quantification of FITC dextran in the sera of unchallenged 10-week-old wild-type and *Prap1*<sup>-/-</sup> mice 4 hours after oral gavage with 4 kilodaltons FITC dextran. Statistical significance was determined using an unpaired *t* test (*n* = 5 mice). IFN, interferon; KC, keratinocyte chemoattractant; RA, relative abundance; TNF, tumor necrosis factor.

Previous literature has reported that PRAP1 acts downstream of p53, protects neoplastic cells from chemotherapeutic agents, and induces cell-cycle arrest.<sup>15</sup> To further identify the mechanism by which PRAP1 protects cells from DNA-damaging agents, we collected RNA from wild-type and *Prap1*<sup>-/-</sup> enteroids 24 hours after irradiation and compared the expression of PRAP1 and other proteins known to be important for cell-cycle arrest. As expected, the wild-type enteroids had strong PRAP1 expression both before and after irradiation (Figure 7D). Interestingly, although both wild-type and *Prap1*<sup>-/-</sup> enteroids showed an increase in *p21*<sup>WAF1/Cip1</sup> expression after irradiation, the *Prap1*<sup>-/-</sup> enteroids had significantly higher *p21* expression compared with wild-type controls (Figure 7E). Expression of *p18*<sup>Ink4c</sup>, another protein implicated in cell-cycle arrest, was not different between wild-type and *Prap1*<sup>-/-</sup> enteroids (Figure 7F). To determine whether this difference in *p21* expression could be observed in a different epithelial model we transiently overexpressed human PRAP1 in a human epithelial cell

line. After 24 hours of PRAP1 overexpression, the cells were irradiated with 8 Gy and cell lysate was collected 48 hours later (Figure 7G). Consistent with our findings in the enteroids, Western blot analysis showed the cells overexpressing PRAP1 had significantly less p21 protein after irradiation (Figure 7H) and no difference in p18 (Figure 7I). Taken together, these data show that PRAP1 protects the epithelium from irradiation-induced apoptosis and significantly limits the amount of p21 expression after challenge.

## Discussion

We report that PRAP1 is an intrinsically disordered protein that is highly expressed in the small intestine of mice and human beings. At homeostasis, *Prap1* null mice show mild physiological differences, with increased cytokine levels and an altered gut microbiota. However, *Prap1* null mice are significantly more susceptible to oxidative insult by ionizing radiation, showing accelerated mortality



and enterocyte apoptosis. In addition, *Prap1<sup>-/-</sup>* enteroids are more susceptible to irradiation-induced apoptosis and have increased p21 expression. These data show that PRAP1 functions as an important component of the epithelial response to oxidative insult.

The study of intrinsically disordered protein (IDP) structure and function is inherently complex because the extended structure of IDPs is flexible and dependent on their environment and subcellular location.<sup>20</sup> Several IDPs have been shown to regulate cell signaling pathways

because their flexible conformation allows them to bind regulatory proteins with disparate functions. The ability of IDPs to weakly bind multiple proteins allows them to facilitate the assembly of cellular signaling complexes that control pathway signaling.<sup>20</sup> For example, p21 is a 21-kilodalton intrinsically disordered protein that has the ability to bind and regulate several cyclin-dependent kinase (CDK)-cyclin complexes and ultimately regulates cell-cycle progression.<sup>21</sup> The ability to bind several proteins affords multiple functions and the regulation of a variety of




complexes. In addition, IDPs also have been implicated in the formation of hydrogels by regulating liquid phase transitions, as well as the formation of non-membrane-bound intracellular granules.<sup>22</sup> Given the intracellular perinuclear localization of PRAP1 in the intestinal epithelial cells, it is possible that PRAP1 functions intracellularly to assemble proteins that function in cell signaling, ultimately regulating the cellular response to oxidative stress and cell-cycle progression. In addition, there is a signal peptide on the N terminus of PRAP1, and our laboratory and others have found that PRAP1 is secreted at relatively high levels into the supernatant of cultured cells.<sup>23</sup> It may be possible that similar to many other IDPs, PRAP1 has multiple functions that are dictated by cellular location and the presence of interacting proteins.

The discovery of novel effector proteins that protect from exogenous insults is a challenging endeavor because the function of these proteins is not apparent *in vivo* at homeostatic conditions. For example, experimental rodents generally are maintained in conditions that minimize exposure to xenobiotic agents or pathogenic microbes.<sup>24</sup> As a result, mice that are null for proteins that confer protection often do not show any spontaneous phenotypes. Rather, it is only in response to exogenous insults that these null mice show phenotypes, typically manifested as increased susceptibility, or failure to recover after insult.<sup>25,26</sup> Although *Prap1*<sup>-/-</sup> mice showed normal epithelial proliferation, apoptosis, and gut permeability at baseline, there were signs of suboptimal intestinal function because inflammatory markers were increased and the upper gastrointestinal microbiota was altered. After challenge with irradiation, underlying suboptimal intestinal functions were exaggerated with a significant increase in epithelial apoptosis, without a corresponding increase in proliferation. Although irradiation is not a naturally occurring challenge for the intestinal epithelium, the mucosa commonly encounters exogenous stressors that increase oxidative stress, and this is especially true for the small intestinal epithelium where PRAP1 expression is highest. The small intestine must tolerate a

myriad of stressors that are introduced by digestive processes, nutrient absorption, and microbial contact.<sup>27</sup> Importantly, these stressors have the potential to significantly increase with a change in diet or gastrointestinal infection.<sup>28-30</sup> Discovering proteins critical to the epithelial response to oxidative insult has the potential to identify therapeutic targets to prevent tissue damage that ultimately results in a leaky gut phenotype. This occurs after the breakdown of the epithelial barrier of the gastrointestinal tract, increasing translocation of luminal antigens, microbes, and their products, which leads to increased local and systemic inflammation.<sup>31</sup> In this study, identifying a protective function for PRAP1 in the gut may allow for the development of effective therapeutics that augment the function of PRAP1, and thereby enhance protection against exogenous stressors.

To elucidate the protective role of PRAP1 in the intestine, we used TBI as a model of exogenous challenge to the intestinal epithelium. TBI generates a large amount of oxidative stress, inducing rapid apoptosis of vulnerable proliferating cells in the bone marrow and intestinal crypts.<sup>32</sup> Loss of the cellular immune system and a compromised intestinal barrier is a combination that leads to rapid weight loss, lack of fluid retention, and increases the risk of developing systemic bacterial infection.<sup>32,33</sup> Although we did not detect an increase in gut permeability 72 hours after irradiation via FITC dextran in the *Prap1*<sup>-/-</sup> mice, we did observe a significant prolonged survival in the wild-type mice after a lethal dose of irradiation compared with the *Prap1*<sup>-/-</sup> littermates. It is probable that a significant defect in the gut barrier as a result of excessive apoptosis immediately precedes necessary end points for humane euthanasia of the mouse, therefore making differences in gut permeability difficult to measure accurately. Although apoptotic cells in the epithelium can be replaced quickly by neighboring epithelial cells,<sup>5</sup> we did not see a corresponding increase in *Pcna* expression in the *Prap1*<sup>-/-</sup> tissue. In addition, we found a significant increase in the expression of p21, a

**Figure 6. (See previous page). *Prap1*<sup>-/-</sup> mice are more susceptible to radiologic challenge and have increased apoptosis in the intestinal epithelium.** (A) Percentage body weight loss of wild-type C57BL/6 and littermate *Prap1*<sup>-/-</sup> mice after 10 Gy TBI. Statistical analysis represents a comparison of wild-type vs *Prap1*<sup>-/-</sup> on each respective day using 2-way analysis of variance, Bonferroni multiple comparisons test (n = 4 mice). \**P* < .05, \*\**P* < .01. (B) Survival of wild-type, *Prap1*<sup>+/-</sup> or *Prap1*<sup>-/-</sup> mice after 10 Gy TBI. Statistical significance was determined using the log-rank test (n ≥ 11 mice). \*\**P* < .01. (C) Representative images of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive cells (green) within the small intestine of 8-week-old wild-type and *Prap1*<sup>-/-</sup> littermates 6 hours after receiving 10 Gy TBI. (D) Representative images of cleaved caspase-3-positive cells (green) within the small intestine of 8-week-old wild-type and *Prap1*<sup>-/-</sup> littermates 72 hours after receiving 10 Gy TBI. (E) Quantification of TUNEL-positive cells in panel C. Significance was determined using an unpaired *t* test (n ≥ 11 mice). \*\**P* < .01. (F) Quantification of cleaved caspase-3-positive cells in panel D. Significance was determined using an unpaired *t* test (n ≥ 6 mice). \*\**P* < .01. (G) Quantification of *Bax* transcript via quantitative PCR on whole tissue from the small intestine of wild-type and *Prap1*<sup>-/-</sup> littermates 96 hours after 10 Gy TBI. Significance was determined using an unpaired *t* test (n = 6 mice). \**P* < .05. (H) Quantification of *Pcna* transcript via quantitative PCR on whole tissue from the small intestine of wild-type and *Prap1*<sup>-/-</sup> littermates 96 hours after 10 Gy TBI. Significance was determined using an unpaired *t* test (n = 6 mice). (I) Quantification of serum FITC dextran in wild-type and *Prap1*<sup>-/-</sup> littermates after oral gavage with 4 kilodaltons FITC dextran 72 hours after 10 Gy TBI. Significance was determined using an unpaired *t* test (n ≥ 3 mice). All data are graphed as the means ± SEM. (J) Quantification of *Prap1* transcript via quantitative PCR on whole tissue from the small intestine of wild-type mice at different time points after 10 Gy TBI. Significance was determined using 1-way analysis of variance, Tukey multiple comparisons test (n = 6 mice). \*\**P* < .005. Bax RA, Bax relative abundance; DAPI, 4',6-diamidino-2-phenylindole; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; KO, knockout; *Pcna* RA, *Pcna* relative abundance; WT, wild-type.



**Figure 7. PRAP1 protects enteroids from irradiation-induced apoptosis by limiting p21 expression.** (A) The percentage of viability of wild-type or *Prap1*<sup>-/-</sup> enteroids 48 hours after 2 Gy. Cell viability was measured using the addition of MTT and the percentage of viability was calculated using the cell viability measured before irradiation. Significance was determined using an unpaired *t* test ( $n \geq 7$  wells). \* $P < .05$ . (B) Representative immunofluorescence images for the detection of cleaved caspase-3 in wild-type and *Prap1*<sup>-/-</sup> enteroids 24 hours after 2 Gy. Examples of cleaved caspase-3-positive enteroids are indicated by a white arrowhead. Scale bar: 1000  $\mu\text{m}$ . (C) Quantification of cleaved caspase-3-positive enteroids in panel B. Each data point represents the percentage of cleaved caspase-3-positive enteroids in a well. Data were pooled from 4 independent experiments. Significance was determined via unpaired *t* test ( $n = 4$  mice per group). \*\* $P < .01$ . (D–F) Quantification of *Prap1* (D), *p21* (E), and *p18* (F) transcript via quantitative PCR in wild-type and *Prap1*<sup>-/-</sup> enteroids 24 hours after 0 Gy and 1 Gy. Significance was determined via an unpaired *t* test. \* $P < .05$ . Each data point represents enteroids harvested from a unique mouse ( $n = 3$  mice per group). (G) Protein levels were determined via Western blot from epithelial cells transfected with an empty cytomegalovirus expression vector (pCMV) pCMV or a cytomegalovirus expression vector encoding PRAP1 (pCMV-PRAP1) 48 hours after 8 Gy. (H and I) Quantification of p21 (H) and p18 (I) protein levels in panel G determined via signal intensity relative to GAPDH. Significance was determined using an unpaired *t* test ( $n = 4$ ). \* $P > .05$ . All data are graphed as means  $\pm$  SEM. Casp3, caspase-3; DAPI, 4',6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KO, knockout; pCMV, empty cytomegalovirus expression vector; WT, wild-type

protein critical to regulating cell-cycle progression. In summary, the *Prap1*<sup>-/-</sup> epithelium shows increased apoptosis for days after irradiation in combination with dysregulation of a critical cell-cycle regulating protein, ultimately affecting survival of the *Prap1*<sup>-/-</sup> mice.

The limitations of the current study are that the complete molecular mechanism whereby PRAP1 confers protection from irradiation remains enigmatic. Because PRAP1 is an IDP, it is likely that PRAP1 has multiple functions and has many interacting proteins based on the localization

and disease context. In an in vitro model, Huang et al<sup>15</sup> have shown PRAP1 to be downstream of p53 activation and that PRAP1 was required to arrest cells in the cell cycle after treatment with fluorouracil, ultimately resulting in less DNA damage and less caspase-dependent apoptosis.<sup>15</sup> Consistently, we observed decreased viability and increased apoptosis in the *Prap1*<sup>-/-</sup> enteroids after irradiation. Recapitulating the in vivo phenotype with ex vivo *Prap1*<sup>-/-</sup> enteroids shows that the mechanism of PRAP1 protection is intrinsic to the epithelium and does not require other systemic host processes to function. Interestingly, both the enteroids and an epithelial cell line had decreased p21 expression in the presence of PRAP1 after irradiation. Although p21 has been shown to bind and affect several different signaling complexes and pathways (attributed to the fact that p21 is also an IDP<sup>34</sup>), the existing literature consistently has shown that p21 can have dual effects regarding the induction of apoptosis. In the context of UVB irradiation, overexpression of p21 led to increased apoptosis in keratinocytes.<sup>35</sup> In addition, multiple studies have shown that p21 overexpression increased apoptosis of cancer cells and rendered them more susceptible to chemotherapeutic drugs.<sup>36,37</sup> Here, our data show that PRAP1 significantly limits p21 expression, thereby preventing irradiation-induced apoptosis. Future studies involving the identification of PRAP1 interacting proteins in intestinal epithelial cells will be extremely valuable in defining the mechanism by which PRAP1 limits p21 expression and protects from oxidative insult.

## Methods

### Production of Recombinant PRAP1

The coding sequence for the secreted form of mouse PRAP1 protein (AA 21–149) was cloned into a pET28a vector with a hexahistidine tag (6xHis) tag on the N terminus of the protein generating pET28a-6xHis-PRAP1. This plasmid was transformed into *Escherichia coli* and expression of PRAP1 was induced using 1 mol/L isopropyl  $\beta$ -D-thiogalactopyranoside at 30°C for 4 hours. *E. coli* was lysed using 6 mol/L guanidine and solubilized with 10 mol/L urea. 6xHis-PRAP1 protein was purified using nickel-nitrilotriacetic acid (Ni-NTA) agarose and the buffer was exchanged using phosphate-buffered saline (PBS). For further purification and analysis, PRAP1 protein was loaded onto a size-exclusion chromatography column S200 10/300 at 0.5 mL/min and equilibrated in PBS. The S200 10/300 column was calibrated with a molecular weight standard containing thyroglobulin (670,000 daltons),  $\gamma$ -globulin (158,000 daltons), ovalbumin (44,000 daltons), myoglobin (17,000 daltons), and vitamin B12 (1350 daltons) (Bio-Rad, Hercules, CA) (Figure 1C).

### Circular Dichroism

Circular dichroism (CD) spectroscopy was monitored by a J-810 CD spectropolarimeter (Jasco, Easton, MD) to examine PRAP1 secondary structure. PRAP1 protein was dialyzed overnight in phosphate buffer (50 mmol/L NaPO<sub>4</sub>, 15 mmol/L NaCl, pH 6.8) at a concentration of 0.44 mg/mL

for all measurements. The CD signal and molar ellipticity was measured from 190 to 260 nm with a 1-mm quartz cuvette at 25°C. Data shown are the average of 3 spectral scans and after buffer subtraction.

### Quantitative Reverse-Transcription Polymerase Chain Reaction Analysis

Murine tissue was homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA) and RNA was isolated using the phenol-chloroform extraction method. Complementary DNA was made using the iScript Reverse Transcription Supermix (Bio-Rad). Real-time polymerase chain reaction (PCR) analysis then was performed using the iQ SYBR Green Supermix on a *MylQ* real-time PCR system (Bio-Rad).  $\beta$ -actin and *Gapdh* were used as housekeeping genes where indicated and all quantification is shown as relative abundance to  $\beta$ -actin or *Gapdh* using the  $\Delta\Delta$ CT analysis method. The primer sequences used were as follows: *Prap1*: 5'-ATCTACAGCTTCGCCATTTCG-3', 5'-GTTTGCCTTTGGTCTTGACAG-3'; *Gapdh*: 5'-TCTCCCTCACAATTTCCATCC-3', 5'-GGGTGCAGCGAAGCTTTATTG-3'; *Actin*: 5'-ACCTTCTACAATGAGCTGCG-3', 5'-CTGGATGGCTACGTACATGG-3'; *Pcna*: 5'-GGCTCTCAAGACCTCATCAA-3', 5'-GAGTAAGCTGTACCAAGGAGAC-3'; *Bax*: 5'-CAAGAAGCTGAGCGAGTGTC-3', 5'-GTCCACGTCAACAATCATCC-3'; *IL12*: 5'-GATGTGCTCTCAGAAGCTAACCC-3', 5'-CCAGTCCACCTCTACAACATAAAA-3'; *p21*: 5'-GTTCCCTTGCCACTTCTTACCT-3', 5'-TCATCCTAGCTGGCCTTAGA-3'; and *p18*: 5'-TAGCCTGATGGAGGCAAATG-3', 5'-CGGACAGCCAACCAACTAA-3'.

### Production of PRAP1 Antisera

Full-length mouse PRAP1 recombinant protein was injected into rabbits after a 70-day protocol, whereupon antibodies were generated and serum was collected following the standard polyclonal package protocol performed by Pocono Rabbit Farms (Canadensis, PA). Rabbit PRAP1 antisera was aliquoted and stored at -80°C. PRAP1 specificity was confirmed via immunofluorescence and immunoblot analysis of tissue samples from wild-type and *Prap1*<sup>-/-</sup> mice.

### Prap1 Whole-Body Knockout Mice

*Prap1* whole-body knockout mice (strain: B6;129S5-*Prap1*<sup>tm1Lex</sup>/Mmucd, 032532-UCD), originally generated by Genentech (South San Francisco, CA), have all 5 exons of the *Prap1* gene targeted by homologous recombination. The mice were resuscitated by the Mutant Mouse Resource and Research Center at UC Davis (MMRC-UC Davis) (Davis, CA). *Prap1* heterozygous mice then were shipped from MMRC-UC Davis and housed within a specific pathogen-free facility at Emory University (Atlanta, GA). *Prap1* heterozygous mice then were backcrossed with wild-type C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) until the mice were determined to be fully congenic using the Speed Congenic 128 SNP Panel (Charles River, Wilmington MA). The *Prap1*<sup>-/-</sup> mouse colony was maintained with heterozygous breeding pairs to provide wild-type littermate controls for all experiments. All animal procedures were approved by the Institutional Animal Care and Use Committee of Emory University.

### Immunoblot Analysis

Immunoblot analysis using the PRAP1 antisera was performed on harvested murine tissues as previously described.<sup>38</sup> PRAP1 protein was detected using a 1:1000 dilution of PRAP1 antisera generated by the laboratory (see earlier) in 5% milk made in Tris-buffered saline plus 0.1% Tween (TBST) (Thermo Fisher Scientific, Waltham, MA).

### Immunofluorescence

Murine tissues were harvested and immediately fixed in methacarn solution to preserve any luminal material. Tissues were embedded in paraffin and sectioned at 5  $\mu$ m. Sections were rehydrated in xylene and ethanol baths before undergoing a blocking step with 5% bovine serum albumin (BSA) in PBS. The primary antibody was diluted in 5% BSA and added to the section overnight at 4°C. The secondary antibody conjugated to an Alexa Fluor was diluted 1:1000 in 5% BSA and added to the sections for 1 hour at room temperature. 4',6-diamidino-2-phenylindole diluted 1:1000 in 5% BSA was added as a counterstain for 5 minutes before the sections were mounted with Prolong Antifade Mountant (Invitrogen) and stored long term at -80°C. Slides were washed 3 times in PBS after each staining step. Images were captured on an FV1000 confocal microscope (Olympus, Tokyo, Japan).

### Immunohistochemistry Staining on Human Sections

Diagnostic curettings of de-identified human tissue were obtained in collaboration with Dr Krisztina Hanley and Dr Brian Robinson (Emory University, Atlanta, GA). Immunohistochemistry was performed by the Cancer Tissue and Pathology Core at Emory University. Human PRAP1 was visualized using a commercially available polyclonal antibody (Proteintech) diluted 1:400.

### Histologic Assessment of Intestinal Architecture

Murine proximal small intestine was fixed with formalin and embedded in paraffin before sectioning and staining with H&E. Approximately 20 independent villi and crypt lengths were obtained from bright-field microscope images using ImageJ (National Institutes of Health, Bethesda, MD).

### Microbiota Analysis

Luminal content from the distal ileum of mice was collected and microbial DNA was isolated using the QIAmp Stool DNA mini kit (Qiagen, Hilden, Germany). Preparation of 16S samples was performed as reported previously.<sup>39</sup> PCR amplification of the 16S ribosomal RNA V4 region was performed using the 515F/806R primer pair (GTGCCAGCMGCCGCGGTAA and GGACTACHVGGGTWTC-TAAT) with a unique 12-base Golay barcode on each reverse primer. DNA concentration was measured using a Qubit fluorometer (ThermoFisher, Waltham, MA) and run on a bioanalyzer to confirm a single 16S band. The DNA was pooled at equimolar ratios and then sequenced using an Illumina Miseq sequencer (San Diego, CA) at the Emory

Integrated Genomics Core (Emory University). Read counts for each sample were generated by uploading the raw sequence files to Illumina's 16S Metagenomics Application on the BaseSpace Sequence Hub platform.

### Measurement of Cytokines and Fecal IgA

Cytokine levels in whole serum from 10-week-old mice were measured using the V-PLEX Proinflammatory Panel 1 Mouse Kit (Meso Scale Discovery, Rockville, MD) following the manufacturer's protocol with the help of the Emory Multiplexed Immunoassay Core (Emory University). For Fecal IgA, fecal pellets were collected from adult mice and vortexed in PBS with 5 mmol/L EDTA to a final concentration of 0.1 mg feces/mL. The samples then were centrifuged at 6000 g for 10 minutes and the supernatant was removed. An IgA enzyme-linked immunosorbent assay kit (Invitrogen) was used to quantify the amount of mouse IgA present in the supernatant following the manufacturer's protocol.

### Measurement of Intestinal Permeability

Adult mice (8 weeks old) were fasted for 12 hours and orally gavaged with 10 mg FITC-conjugated dextran (4 kilodaltons) dissolved in PBS. After 4 hours the mice were killed and serum was diluted 1:4 with PBS. The quantity of FITC-dextran was determined by using a spectrophotometer capable of 485-nm excitation and 528-nm emission. The final concentration was calculated by comparison with a FITC-dextran standard curve. For irradiation experiments, mice were fasted for 4 hours on day 3 before oral gavage with FITC-dextran.

### TBI Challenge

*Prap1*<sup>-/-</sup> and wild-type littermate controls at 8 weeks of age received 10 G radiation (225 kV and 17.7 mA) using a RS2000 X-ray irradiator (Rad Source Technologies, Buford, GA). Weight loss was monitored daily and the mice were killed once they reached 75% of their initial body weight. Apoptotic cells were visualized in tissue sections collected 6 hours after radiation challenge using the In Situ Cell Death detection kit (Roche, Basel, Switzerland) and quantified by counting the number of positive cells per crypt in 10 random fields of view per mouse ( $n \geq 9$  mice) at 400 $\times$  total magnification on an FV1000 confocal fluorescence microscope (Olympus). Cleaved caspase-3-positive cells were visualized 72 hours after radiation challenge using the polyclonal cleaved caspase-3 antibody from Cell Signaling (Danvers, MA). By using a total magnification of 200 $\times$ , the number of positive cells in 120 random villi was enumerated for each mouse ( $n \geq 6$  mice), and, assuming an average of 86 enterocytes per villi, the proportion of positive cells was calculated.

### Generation of Enteroids

Enteroids from wild-type and *Prap1*<sup>-/-</sup> littermates were generated using the IntestiCult Organoid Growth Medium (mouse) from StemCell Technologies (Vancouver, Canada) following the manufacturer's provided protocol. Briefly, the

entire length of the small intestine was dissected, washed, and digested for the collection of small intestinal crypts. The crypts were enumerated and combined with a 1:1 ratio of Intesticult Organoid Growth Medium and Matrigel (Corning, Tewksbury, MA). Media was refreshed every 2 days and enteroids were passaged every 7 days. For irradiation experiments, enteroids were irradiated on days 4–5 of culture.

### Assessment of Enteroid Viability

Enteroid viability was assessed by quantification of MTT reduction to formazan following the protocol described by Grabinger et al.<sup>40</sup> Briefly, after treatment with either irradiation or a staurosporine-positive control, sterile MTT was added at a final concentration of 500  $\mu\text{g}/\text{mL}$  for 1 hour at 37°C. Cell media then was replaced with 2% sodium dodecyl sulfate to digest the Matrigel and then dimethyl sulfoxide was added to solubilize the formazan. Each well then was read at 563 nm using a spectrophotometer and the positive control optical density was subtracted from each reading. The percentage of viability was calculated by dividing the optical density of the treatment wells by the optical density of untreated wells, multiplied by 100.

### Whole-Mount Immunofluorescence Staining of Enteroids

The immunofluorescence staining protocol was adapted from O'Rourke et al.<sup>41</sup> and modified for staining and imaging in a 96-well plate. Enteroids were grown and treated in 96-well plates and on the day of staining media was replaced with 80  $\mu\text{L}$  4% paraformaldehyde and fixed for 20 minutes at room temperature. Enteroids then were washed with IF buffer and permeabilized for 20 minutes at room temperature with 80  $\mu\text{L}$  0.5% Triton X-100 (Thermo Fisher Scientific) in PBS. By this point, the Matrigel was dissolved and the enteroids remained attached to the bottom of the well. After washing with IF buffer, the enteroids were blocked for 30 minutes at room temperature with 5% BSA in PBS. The primary antibody specific for cleaved caspase-3 (Cell Signaling) was diluted 1:100 in blocking solution and incubated overnight at 4°C. After washing with IF buffer, secondary antibody specific for rabbit IgG was diluted 1:1000 in blocking buffer for 1 hour at room temperature, protected from light. Secondary antibody was removed and 4',6-diamidino-2-phenylindole diluted 1:1000 in PBS was added for 10 minutes protected from light. The enteroids then were washed with IF buffer and then with PBS. PBS was left in the well during imaging on a Lionheart FX Automated Microscope (BioTek, Winooski, VT).

### Preparation of Enteroids for RNA Isolation

Enteroids were grown in 24-well plates and collected using 1 mL ice-cold PBS. Enteroids from at least 4 wells were pooled into a 15-mL conical tube and spun at 500  $\times g$  for 5 minutes, at 4°C. The supernatant was carefully collected while also collecting as much Matrigel as possible above the enteroid pellet. One milliliter of fresh cold PBS was slowly added to the tube to lift any remaining Matrigel off the enteroid pellet. All remaining PBS/Matrigel was

carefully collected, leaving the enteroid pellet undisturbed. The enteroid pellet was collected with 300  $\mu\text{L}$  TRIzol and transferred to a 1.7-mL Eppendorf tube. The enteroids were sonicated twice for 5 seconds, resting on ice in between. The RNA was isolated and quantitative PCR was performed as described earlier.

### Overexpression of Human PRAP1

A human colonic epithelial cell line (SK-CO15) was grown to confluence in a 24-well plate before the addition of 2  $\mu\text{L}$  Lipofectamine 2000 (Invitrogen) with 1  $\mu\text{g}$  plasmid DNA. Cells were transfected with either an empty cytomegalovirus expression plasmid with a c-terminal myc tag (pCMV-myc), pCMV-PRAP1-myc to transiently overexpress human PRAP1, or pCMV-green fluorescent protein (GFP) to monitor the success of the transfection. After an overnight transfection, media was refreshed and 6 hours later subjected to 8 Gy of radiation (225 kV and 17.7 mA) using a RS2000 X-ray irradiator (Rad Source Technologies). After 48 hours the cells were washed with cold PBS and collected with RIPA buffer (Thermo Fisher Scientific) and Western blot was performed as previously described.<sup>38</sup> PRAP1 was detected by immunoblot with the commercially available anti-PRAP1 antibody (Proteintech) diluted 1:1000 in 5% milk and TBST. Glyceraldehyde-3-phosphate dehydrogenase was detected using a rabbit monoclonal antibody (Cell Signaling) diluted 1:5000 in 5% milk and TBST while all other proteins were detected using the Cell Cycle Regulation Antibody Sampler Kit from Cell Signaling following the manufacturer's protocol. Quantification of bands was performed by measuring the signal intensity with ImageJ software, and calculated as the signal intensity relative to glyceraldehyde-3-phosphate dehydrogenase.

### Statistical Analysis

Cumulative data were graphed as means  $\pm$  SEM, with significance determined via the Student unpaired *t* test or analysis of variance if comparing more than 2 groups. Multiple comparisons used either the Tukey multiple comparisons test or the Dunnett multiple comparisons test when appropriate. Survival curves were compared using the log-rank (Mantel-Cox) test. All statistical tests were performed using GraphPad Prism 8.0.1 (San Diego, CA). A *P* value of .05 or less was considered significant.

### Access to Data

All authors had access to the study data and reviewed and approved the final manuscript.

### References

1. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? *Physiol Rev* 2008;88:1547–1565.
2. Jones RM, Desai C, Darby TM, Luo L, Wolfarth AA, Scharer CD, Ardita CS, Reedy AR, Keebaugh ES, Neish AS. Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. *Cell Rep* 2015;12:1217–1225.

3. Aw TY. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. *Toxicol Appl Pharmacol* 2005;204:320–328.
4. Beyfuss K, Hood DA. A systematic review of p53 regulation of oxidative stress in skeletal muscle. *Redox Rep* 2018;23:100–117.
5. Edelblum KL, Yan F, Yamaoka T, Polk DB. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. *Inflamm Bowel Dis* 2006;12:413–424.
6. Soderholm JD, Perdue MH. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. *Am J Physiol Gastrointest Liver Physiol* 2001;280:G7–G13.
7. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterol* 2014;14:189.
8. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol* 2014;14:141–153.
9. Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gomez-Reino JJ, Mera A, Lago F, Gomez R, Gualillo O. Leptin in the interplay of inflammation, metabolism and immune system disorders. *Nat Rev Rheumatol* 2017;13:100–109.
10. Hernandez-Chirlaque C, Aranda CJ, Ocon B, Capitan-Canadas F, Ortega-Gonzalez M, Carrero JJ, Suarez MD, Zarzuelo A, Sanchez de Medina F, Martinez-Augustin O. Germ-free and antibiotic-treated mice are highly susceptible to epithelial injury in DSS colitis. *J Crohns Colitis* 2016;10:1324–1335.
11. Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, Walker MR, Marinshaw JM, Stappenbeck TS, Stenson WF. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. *Gut* 2012;61:829–838.
12. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990;215:403–410.
13. Zhang J, Rajkumar N, Hooi SC. Characterization and expression of the mouse pregnant specific uterus protein gene and its rat homologue in the intestine and uterus. *Biochim Biophys Acta* 2000;1492:526–530.
14. Kasik J, Rice E. A novel complementary deoxyribonucleic acid is abundantly and specifically expressed in the uterus during pregnancy. *Am J Obstet Gynecol* 1997;176:452–456.
15. Huang BH, Zhuo JL, Leung CH, Lu GD, Liu JJ, Yap CT, Hooi SC. PRAP1 is a novel executor of p53-dependent mechanisms in cell survival after DNA damage. *Cell Death Dis* 2012;3:e442.
16. Xiong GF, Zhang YS, Han BC, Chen W, Yang Y, Peng JP. Estradiol-regulated proline-rich acid protein 1 is repressed by class I histone deacetylase and functions in peri-implantation mouse uterus. *Mol Cell Endocrinol* 2011;331:23–33.
17. Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. *Biochim Biophys Acta* 2010;1804:996–1010.
18. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. *Nat Protoc* 2006;1:2876–2890.
19. Herrero J, Muffato M, Beal K, Fitzgerald S, Gordon L, Pignatelli M, Vilella AJ, Searle SM, Amode R, Brent S, Spooner W, Kulesha E, Yates A, Flicek P. Ensembl comparative genomics resources. *Database (Oxford)* 2016;2016:1–17.
20. Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. *Nat Rev Mol Cell Biol* 2015;16:18–29.
21. Yoon MK, Mitrea DM, Ou L, Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. *Biochem Soc Trans* 2012;40:981–988.
22. Weber SC, Brangwynne CP. Getting RNA and protein in phase. *Cell* 2012;149:1188–1191.
23. Zhang J, Wong H, Ramanan S, Cheong D, Leong A, Hooi SC. The proline-rich acidic protein is epigenetically regulated and inhibits growth of cancer cell lines. *Cancer Res* 2003;63:6658–6665.
24. Rosshart SP, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K, Hickman HD, McCulloch JA, Badger JH, Ajami NJ, Trinchieri G, Pardo-Manuel de Villena F, Yewdell JW, Rehmann B. Wild mouse gut microbiota promotes host fitness and improves disease resistance. *Cell* 2017;171:1015–1028 e13.
25. Wang L, Fouts DE, Starkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. *Cell Host Microbe* 2016;19:227–239.
26. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. *Science* 1996;274:262–265.
27. Madesh M, Benard O, Balasubramanian KA. Apoptotic process in the monkey small intestinal epithelium: 2. Possible role of oxidative stress. *Free Radic Biol Med* 1999;26:431–438.
28. Sodhi CP, Fulton WB, Good M, Vurma M, Das T, Lai CS, Jia H, Yamaguchi Y, Lu P, Prindle T, Ozolek JA, Hackam DJ. Fat composition in infant formula contributes to the severity of necrotising enterocolitis. *Br J Nutr* 2018;120:665–680.
29. Li X, Wei X, Sun Y, Du J, Li X, Xun Z, Li YC. High-fat diet promotes experimental colitis by inducing oxidative stress in the colon. *Am J Physiol Gastrointest Liver Physiol* 2019;317:G453–G462.
30. Ma'ayeh SY, Knorr L, Skold K, Garnham A, Ansell BRE, Jex AR, Svard SG. Responses of the differentiated intestinal epithelial cell line Caco-2 to infection with the *Giardia intestinalis* GS isolate. *Front Cell Infect Microbiol* 2018;8:244.
31. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. *Gut* 2019;68:1516–1526.
32. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, Kirsch DG, Macvittie TJ, Mason KA, Medhora MM, Moulder JE, Okunieff P, Otterson MF, Robbins ME, Smathers JB, McBride WH. Animal models for medical countermeasures to radiation exposure. *Radiat Res* 2010;173:557–578.

33. Vriesendorp HM, Vigneulle RM, Kitto G, Pelky T, Taylor P, Smith J. Survival after total body irradiation: effects of irradiation of exteriorized small intestine. *Radiother Oncol* 1992;23:160–169.
34. Follis AV, Galea CA, Kriwacki RW. Intrinsic protein flexibility in regulation of cell proliferation: advantages for signaling and opportunities for novel therapeutics. *Adv Exp Med Biol* 2012;725:27–49.
35. Chen A, Huang X, Xue Z, Cao D, Huang K, Chen J, Pan Y, Gao Y. The role of p21 in apoptosis, proliferation, cell cycle arrest, and antioxidant activity in UVB-irradiated human HaCaT keratinocytes. *Med Sci Monit Basic Res* 2015;21:86–95.
36. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. *Oncogene* 1995;11:1899–1905.
37. Choi YH, Yoo YH. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. *Oncol Rep* 2012;28:2163–2169.
38. Matthews JD, Owens JA, Naudin CR, Saeedi BJ, Alam A, Reedy AR, Hinrichs BH, Sumagin R, Neish AS, Jones RM. Neutrophil-derived reactive oxygen orchestrates epithelial cell signaling events during intestinal repair. *Am J Pathol* 2019;189:2221–2232.
39. Alam A, Leoni G, Quiros M, Wu H, Desai C, Nishio H, Jones RM, Nusrat A, Neish AS. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. *Nat Microbiol* 2016;1:15021.
40. Grabinger T, Delgado E, Brunner T. Analysis of cell death induction in intestinal organoids in vitro. *Methods Mol Biol* 2016;1419:83–93.
41. O'Rourke KP, Dow LE, Lowe SW. Immunofluorescent staining of mouse intestinal stem cells. *Bio Protoc* 2016;6:e1732.

Received January 16, 2020. Accepted June 29, 2020.

#### Correspondence

Address correspondence to: Andrew S. Neish, MD, Emory University School of Medicine, Whitehead Biomedical Research Building, 615 Michaels Street, Room 105-A, Atlanta, Georgia 30322. e-mail: [aneish@emory.edu](mailto:aneish@emory.edu); fax: (404) 727-8538.

#### CRedit Authorship Contributions

Alexandra A. Wolfarth (Conceptualization: Equal; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Validation: Lead; Visualization: Lead; Writing investigation: Lead; Methodology: Lead; Validation: Lead; Vis; Xu Liu, PhD (Data curation: Supporting; Formal analysis: Supporting; Methodology: Supporting; Visualization: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting); Trevor M. Darby, PhD (Data curation: Supporting; Formal analysis: Supporting; Validation: Supporting); Darra J. Boyer (Data curation: Supporting); Jocelyn B. Spizman (Data curation: Supporting); Joshua A. Owens (Data curation: Supporting; Visualization: Supporting); Bindu Chandrasekharan, PhD (Data curation: Supporting; Writing original draft: Supporting); Crystal R. Naudin, PhD (Data curation: Supporting; Methodology: Supporting); Krisztina Z. Hanley, MD (Resources: Supporting); Brian S. Robinson, MD, Ph.D. (Resources: Supporting); Eric A. Ortlund, PhD (Project administration: Supporting; Supervision: Supporting; Writing project administration: Support; Rheinalt M. Jones, PhD (Conceptualization: Supporting; Methodology: Supporting; Supervision: Supporting; Writing : Supporting; Methodology: Supporting;ng;orting;ng –t.II Supporting); Andrew Neish, MD (Conceptualization: Lead; Funding acquisition: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Writing – original draft: Lead; Writing : Lead; Resources: Lead;.

#### Author contributions

Andrew S. Neish and Alexandra A. Wolfarth conceived the study; Andrew S. Neish, Eric A. Ortlund, and Alexandra A. Wolfarth designed the experiments; Alexandra A. Wolfarth, Xu Liu, Trevor M. Darby, Darra J. Boyer, Jocelyn B. Spizman, Joshua A. Owens, Bindu Chandrasekharan, and Crystal R. Naudin conducted the experiments; Alexandra A. Wolfarth, Xu Liu, and Darra J. Boyer acquired and analyzed the data; Krisztina Z. Hanley and Brian S. Robinson provided reagents; and Andrew S. Neish, Rheinalt M. Jones, and Alexandra A. Wolfarth drafted the manuscript.

#### Conflicts of interest

The authors disclose no conflicts.

#### Funding

Supported by American Heart Association postdoctoral fellowship 17POST33660110 (X.L.); by the Crohn's and Colitis Foundation Award (T.M.D.); by American Heart Association fellowship 19POST34370006 (C.R.N.); and supported in part by National Institutes of Health grants R01DK095750 (E.A.O.), R01DK098391 and R01CA179424 (R.M.J.), and R01DK071604 and R01AI064462 (A.S.N.).